Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Nakamura
T
T
Ushiyama
C
C
Osada
S
S
Shimada
N
N
Ebihara
I
I
Koide
H
H
D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D005905:Glyburide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D006435:Renal Dialysis; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D005905:Glyburide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D013844:Thiazoles; D045162:Thiazolidinediones; D014280:Triglycerides